Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Forensic Toxicology
Published in: Forensic Toxicology 1/2017

01-01-2017 | Original Article

Urinary cannabinoid levels during nabiximols (Sativex®)-medicated inpatient cannabis withdrawal

Authors: Richard C. Kevin, David J. Allsop, Nicholas Lintzeris, Adrian J. Dunlop, Jessica Booth, Iain S. McGregor

Published in: Forensic Toxicology | Issue 1/2017

Login to get access

Abstract

Nabiximols (Sativex®) is a buccal spray containing both ∆9-tetrahydrocannabinol (THC) and cannabidiol (CBD). It has shown promise as an agonist substitution therapy for treating cannabis withdrawal and dependence. Monitoring urinary cannabinoid levels during treatment is important for determination of cannabinoid pharmacokinetics and for treatment adherence during clinical trials. Here, we use a recently described hydrolysis method to liberate urinary CBD from its glucuronide conjugate, and describe the trajectory of urinary CBD, THC, 11-nor-9-carboxy-THC (THC-COOH), and 11-hydroxy-THC (11-OH-THC) in patients receiving nabiximols treatment (or placebo) during cannabis withdrawal. Urine and plasma samples were taken before and during a 6-day inpatient treatment regime and during a 3-day drug-free washout. Urine was hydrolysed with red abalone β-glucuronidase, and CBD, THC, THC-COOH, and 11-OH-THC were quantified in daily urine using liquid chromatography-tandem mass spectrometry. Overall, urine and plasma cannabinoid levels followed similar trajectories and closely reflected the dosing schedule. During nabiximols treatment, CBD levels in urine and plasma rose markedly, while concentrations of THC and its metabolites remained at, or slightly above, pre-treatment levels. Following hydrolysis, urinary CBD was detected at levels 50 and 200 times as high as those in non-hydrolysed plasma and non-hydrolysed urine, respectively. THC, THC-COOH, and 11-OH-THC concentrations were also amplified by urinary hydrolysis. This method allows sensitive assessment of urinary CBD, and may prove useful in clinical studies involving nabiximols or other cannabinoid therapies.
Appendix
Available only for authorised users
Literature
1.
2.
Degenhardt L, Ferrari AJ, Calabria B, Hall WD, Norman RE, McGrath J, Flaxman AD, Engell RE, Freedman GD, Whiteford HA, Vos T (2013) The global epidemiology and contribution of cannabis use and dependence to the global burden of disease: results from the GBD 2010 study. PLoS One 8:e76635. doi:10.​1371/​journal.​pone.​0076635 CrossRefPubMedPubMedCentral
3.
4.
Allsop DJ, Norberg MM, Copeland J, Fu S, Budney AJ (2011) The cannabis withdrawal scale development: patterns and predictors of cannabis withdrawal and distress. Drug Alcohol Depend 119:123–129CrossRefPubMed
5.
Levin KH, Copersino ML, Heishman SJ, Liu F, Kelly DL, Boggs DL, Gorelick DA (2010) Cannabis withdrawal symptoms in non-treatment-seeking adult cannabis smokers. Drug Alcohol Depend 111:120–127CrossRefPubMedPubMedCentral
6.
Budney AJ, Vandrey RG, Hughes JR, Thostenson JD, Bursac Z (2008) Comparison of cannabis and tobacco withdrawal: severity and contribution to relapse. J Subst Abuse Treat 35:362–368CrossRefPubMedPubMedCentral
7.
8.
Haney M, Ward AS, Comer SD, Hart CL, Foltin RW, Fischman MW (2001) Bupropion SR worsens mood during marijuana withdrawal in humans. Psychopharmacology 155:171–179CrossRefPubMed
9.
10.
11.
Allsop DJ, Lintzeris N, Copeland J, Dunlop A, McGregor IS (2015) Cannabinoid replacement therapy (CRT): nabiximols (Sativex) as a novel treatment for cannabis withdrawal. Clin Pharmacol Ther 97:571–574CrossRefPubMed
12.
Budney AJ, Vandrey RG, Hughes JR, Moore BA, Bahrenburg B (2007) Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug Alcohol Depend 86:22–29CrossRefPubMed
13.
Haney M, Cooper ZD, Bedi G, Vosburg SK, Comer SD, Foltin RW (2013) Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse. Neuropsychopharmacology 38:1557–1565CrossRefPubMedPubMedCentral
14.
15.
Fusar-Poli P, Crippa JA, Bhattacharyya S, Borgwardt SJ, Allen P, Martin-Santos R, Seal M, Surguladze SA, O’Carrol C, Atakan Z, Zuardi AW, McGuire PK (2009) Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry 66:95–105CrossRefPubMed
16.
Morgan CJ, Schafer G, Freeman TP, Curran HV (2010) Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study. Br J Psychiatry 197:285–290CrossRefPubMed
17.
Zuardi AW, Crippa JA, Hallak JE, Bhattacharyya S, Atakan Z, Martin-Santos R, McGuire PK, Guimaraes FS (2012) A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation. Curr Pharm Des 18:5131–5140CrossRefPubMed
18.
Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM (2015) Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol 172:4790–4805CrossRefPubMedPubMedCentral
19.
Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, Klosterkötter J, Hellmich M, Koethe D (2012) Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatr 2:e94. doi:10.​1038/​tp.​2012.​15 CrossRef
20.
O’Sullivan SE, Kendall DA (2010) Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease. Immunobiology 215:611–616CrossRefPubMed
21.
Iannotti FA, Hill CL, Leo A, Alhusaini A, Soubrane C, Mazzarella E, Russo E, Whalley BJ, Di Marzo V, Stephens GJ (2014) Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability. ACS Chem Neurosci 5:1131–1141CrossRefPubMed
22.
Hassan S, Eldeeb K, Millns PJ, Bennett AJ, Alexander SPH, Kendall DA (2014) Cannabidiol enhances microglial phagocytosis via transient receptor potential (TRP) channel activation. Br J Pharmacol 171:2426–2439CrossRefPubMedPubMedCentral
23.
Stout SM, Cimino NM (2014) Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev 46:86–95CrossRefPubMed
24.
Watanabe K, Yamaori S, Funahashi T, Kimura T, Yamamoto I (2007) Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. Life Sci 80:1415–1419CrossRefPubMed
25.
Williams PL, Moffat AC (1980) Identification in human urine of Δ9-tetrahydrocannabinol-11-oic acid glucuronide: a tetrahydrocannabinol metabolite. J Pharm Pharmacol 32:445–448CrossRefPubMed
26.
Mazur A, Lichti CF, Prather PL, Zielinska AK, Bratton SM, Gallus-Zawada A, Finel M, Miller GP, Radominska-Pandya A, Moran JH (2009) Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids. Drug Metab Dispos 37:1496–1504CrossRefPubMedPubMedCentral
27.
Harvey DJ, Mechoulam R (1990) Metabolites of cannabidiol identified in human urine. Xenobiotica 20:303–320CrossRefPubMed
28.
Bergamaschi MM, Barnes A, Queiroz RH, Hurd YL, Huestis MA (2013) Impact of enzymatic and alkaline hydrolysis on CBD concentration in urine. Anal Bioanal Chem 405:4679–4689CrossRefPubMedPubMedCentral
29.
Allsop DJ, Copeland J, Lintzeris N, Dunlop AJ, Montebello M, Sadler C, Rivas GR, Holland RM, Muhleisen P, Norberg MM, Booth J, McGregor IS (2014) Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. JAMA Psychiatry 71:281–291CrossRefPubMed
30.
Bell ML, Fairclough DL (2014) Practical and statistical issues in missing data for longitudinal patient-reported outcomes. Stat Methods Med Res 23:440–459CrossRefPubMed
31.
Hedges LV (1981) Distribution theory for Glass’s estimator of effect size and related estimators. J Educ Behav Stat 6:107–128CrossRef
32.
33.
34.
Desrosiers NA, Himes SK, Scheidweiler KB, Concheiro-Guisan M, Gorelick DA, Huestis MA (2014) Phase I and II cannabinoid disposition in blood and plasma of occasional and frequent smokers following controlled smoked cannabis. Clin Chem 60:631–643CrossRefPubMed
35.
Grauwiler SB, Scholer A, Drewe J (2007) Development of a LC/MS/MS method for the analysis of cannabinoids in human EDTA-plasma and urine after small doses of Cannabis sativa extracts. J Chromatogr B 850:515–522CrossRef
36.
Bergamaschi MM, Karschner EL, Goodwin RS, Scheidweiler KB, Hirvonen J, Queiroz RH, Huestis MA (2013) Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers’ blood on per se drugged driving laws. Clin Chem 59:519–526CrossRefPubMedPubMedCentral
37.
Lemberger L, Tamarkin NR, Axelrod J, Kopin IJ (1971) Delta-9-tetrahydrocannabinol: metabolism and disposition in long-term marihuana smokers. Science 173:72–74CrossRefPubMed
38.
39.
Wong A, Keats K, Rooney K, Hicks C, Allsop DJ, Arnold JC, McGregor IS (2014) Fasting and exercise increase plasma cannabinoid levels in THC pre-treated rats: an examination of behavioural consequences. Psychopharmacology 231:3987–3996CrossRefPubMed
40.
Johansson E, Noren K, Sjovall J, Halldin MM (1989) Determination of Δ1-tetrahydrocannabinol in human fat biopsies from marihuana users by gas chromatography-mass spectrometry. Biomed Chromatogr 3:35–38CrossRefPubMed
41.
42.
43.
Scheidweiler KB, Desrosiers NA, Huestis MA (2012) Simultaneous quantification of free and glucuronidated cannabinoids in human urine by liquid chromatography tandem mass spectrometry. Clin Chim Acta 413:1839–1847CrossRefPubMedPubMedCentral
44.
Huestis MA, Cone EJ (1998) Urinary excretion half-life of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol in humans. Ther Drug Monit 20:570–576CrossRefPubMed
45.
Friedman D, Devinsky O (2015) Cannabinoids in the treatment of epilepsy. N Engl J Med 373:1048–1058CrossRefPubMed
46.
Trigo JM, Lagzdins D, Rehm J, Selby P, Gamaleddin I, Fischer B, Barnes AJ, Huestis MA, Le Foll B (2016) Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings. Drug Alcohol Depend 161:298–306CrossRefPubMed
47.
Lee D, Karschner EL, Milman G, Barnes AJ, Goodwin RS, Huestis MA (2013) Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration? Drug Alcohol Depend 130:68–76CrossRefPubMed
48.
Bruci Z, Papoutsis I, Athanaselis S, Nikolaou P, Pazari E, Spiliopoulou C, Vyshka G (2012) First systematic evaluation of the potency of Cannabis sativa plants grown in Albania. Forensic Sci Int 222:40–46CrossRefPubMed
49.
50.
Tsumura Y, Aoki R, Tokieda Y, Akutsu M, Kawase Y, Kataoka T, Takagi T, Mizuno T, Fukada M, Fujii H, Kurahashi K (2012) A survey of the potency of Japanese illicit cannabis in fiscal year 2010. Forensic Sci Int 221:77–83CrossRefPubMed
51.
Novotna A, Mares J, Ratcliffe S, Novakova I, Vachova M, Zapletalova O, Gasperini C, Pozzilli C, Cefaro L, Comi G, Rossi P, Ambler Z, Stelmasiak Z, Erdmann A, Montalban X, Klimek A, Davies P, Sativex Spasticity Study Group (2011) A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 18:1122–1131CrossRefPubMed
Metadata
Title
Urinary cannabinoid levels during nabiximols (Sativex®)-medicated inpatient cannabis withdrawal
Authors
Richard C. Kevin
David J. Allsop
Nicholas Lintzeris
Adrian J. Dunlop
Jessica Booth
Iain S. McGregor
Publication date
01-01-2017
Publisher
Springer Japan
Published in
Forensic Toxicology / Issue 1/2017
Print ISSN: 1860-8965
Electronic ISSN: 1860-8973
DOI
https://doi.org/10.1007/s11419-016-0330-0

Other articles of this Issue 1/2017

Forensic Toxicology 1/2017 Go to the issue

Review Article

Metabolites replace the parent drug in the drug arena. The cases of fonazepam and nifoxipam

Original Article

In vitro and in vivo human metabolism of a new synthetic cannabinoid NM-2201 (CBL-2201)

Erratum

Erratum to: Analysis of 62 synthetic cannabinoids by gas chromatography–mass spectrometry with photoionization

Review Article

U-47700. An old opioid becomes a recent danger

Original Article

Simultaneous determination of insulin, DesB30 insulin, proinsulin, and C-peptide in human plasma samples by liquid chromatography coupled to high resolution mass spectrometry

Short Communication

Simple regioisomeric differentiation of 2-, 3- and 4-methyl-α-pyrrolidinobutiophenones by gas chromatography–mass spectrometry using bromination